Improved Disease-modifying Therapies Through Joint Pharmacophore Mining

Acelot is a life science based R&D company focusing on advanced technology for drug discovery. This technology is made available both as an easy-to-use web-based drug discovery platform, as well as employed in-house for a number of drug-discovery projects in the central nervous system area.

jps_screen At the core of Acelot's technology is a novel and unique computer algorithm, "JPS", that has been developed at the University of California and was validated in a variety of studies. JPS allows the identification of latent pharmacophore information and can be used for rapid lead identification and optimization even for drug development projects without clear target information or crystallography data. Furthermore, JPS is useful for screening against undesired pathways and targets to minimize the risk of side-effects. Additional information on the underlying technology can be found here.

leads_platform Acelot also provides on-site or remote drug discovery services around the JPS technology. These services include pharmacophore development, drug repurposing/retargeting, SAR interpretation and optimization, and PKDM and ADME/Tox prediction. A web-based drug discovery platform based on Acelot's unique technology will open in the second half of 2014. Additional information can be found here.

drug_pipeline Acelot's own JPS-powered drug discovery pipeline comprises several compound families for Alzheimer's and Parkinson's disease. These compounds span a variety of mechanisms-of-action and have been validated in a number of in-vitro assays to date. Acelot is actively looking for potential development partners for any of these compound families. Additional information can be found here.


December 22, 2015
U.S. patent 9,218,460 on the JPS method has been granted with Ambuj Singh as one of the inventors. Acelot holds an exclusive license for this patent.

May 31, 2015
Acelot co-authored an article in Bioorganic & Medicinal Chemistry Letters on the use of its unique JPS technology for the discovery of novel LRRK2 inhibitors for the treatment of Parkinson's disease.

December 3, 2013
Congresswoman Lois Capps (CA-24) highlights Acelot's recently funded project on building a web-based drug discovery platform as an example of applying innovation to the nation's healthcare needs. Read more here.